1.06

3.92% 0.04

After Hours: 1.05 -0.01 -0.94%

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $1.06, with a volume of 766.23K. It is up +3.92% in the last 24 hours and down -28.86% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$1.02

Open:

$1.01

24h Volume:

766.23K

Relative Volume:

0.55

Market Cap:

$28.70M

Revenue:

$642.00K

Net Income/Loss:

$-69.90M

P/E Ratio:

-0.1482

EPS:

-7.152

Net Cash Flow:

$-57.62M

1W Performance:

-2.75%

1M Performance:

-28.86%

6M Performance:

-59.54%

1Y Performance:

-44.79%

1-Day Range:

$1.01

$1.08

1-Week Range:

$1.01

$1.18

52-Week Range:

$1.01

$8.08

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1110)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2026-03-26

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	1.06	28.70M	642.00K	-69.90M	-57.62M	-7.152
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Initiated	Rodman & Renshaw	Buy
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

Apr 13, 2026

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance

Apr 13, 2026

Apr 10, 2026

H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Apr 10, 2026

H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Apr 10, 2026

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz

Apr 10, 2026

BioXcel Therapeutics, Inc. Share Price TodayLive NASDAQ: BTAI Stock Price Charts, History - Upstox

Apr 10, 2026

Apr 09, 2026

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm

Apr 09, 2026